{
    "clinical_study": {
        "@rank": "158242", 
        "arm_group": [
            {
                "arm_group_label": "First NGM/EE (Wet Process), then NGM/EE (Dry Process)", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive 1 tablet (formulated by wet process) containing norgestimate 250 microgram (mcg) and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days."
            }, 
            {
                "arm_group_label": "First NGM/EE (Dry Process), then NGM/EE (Wet Process)", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by wet process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish the bioequivalence of the hormones norgestimate,\n      norelgestromin, and ethinyl estradiol in norgestimate/ethinyl estradiol (NGM/EE) tablets,\n      formulated by wet process compared with the same hormones in NGM/EE tablets, formulated by\n      dry process, in healthy women."
        }, 
        "brief_title": "A Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different Facilities", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This is a Phase 1, single-dose, open-label (a medical research study in which participants\n      and researchers are told which treatments the participants are receiving, \"unblinded\"),\n      randomized (the study medication is assigned by chance), single-center and a 2-way crossover\n      (method used to switch participants from one study group to another in a clinical trial)\n      study in healthy women. The study consists of 3 parts:  Screening phase, Treatment phase and\n      end-of-study or withdrawal. Treatment periods will be separated by a wash out period of at\n      least 10 days. The duration of participation in the study for an individual participant will\n      be approximately 7 weeks. All participants will be randomly assigned in a 1:1 ratio to 1 of\n      2 possible treatment sequences and receive both of the following treatments: 1 oral tablet\n      formulated by wet process or dry process, whereas each tablet contains norgestimate 250\n      microgram (mcg) and ethinyl estradiol 35 mcg. The primary endpoint of the study will be\n      assessment of pharmacokinetic parameters. Participants' safety will be monitored throughout\n      the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants must be either surgically sterile or of child-bearing potential and be\n             practicing an effective non-hormonal method of birth control (for example, copper\n             intrauterine device, double-barrier method, male partner sterilization) before entry\n             and throughout the study\n\n          -  If a woman of child-bearing potential, must have a negative serum beta-human\n             chorionic gonadotropin (hCG) pregnancy test at screening; and a negative urine\n             pregnancy test on Day -1 of the each treatment period\n\n          -  Participants must agree not to donate eggs (ova, oocytes) for the purposes of\n             assisted reproduction during the study and for 3 months after the last dose\n\n          -  Body mass index (BMI: weight [kilogram {kg}]/height^2 [meter {m}]^2) between 18.5 and\n             30 kg/m^2 (inclusive), and body weight not less than 50 kilogram (kg) or higher than\n             90 kg (198 pounds)\n\n          -  Participant must be a non-smoker\n\n        Exclusion Criteria:\n\n          -  Participants have a levonorgestrel implant (for example, Norplant) in place or\n             removed within the 30 days before admission to the study site\n\n          -  Contraindications to combined hormonal contraceptives\n\n          -  Participants who received medroxyprogesterone injection (for example, Depo Provera)\n             within 6 months of admission to the study\n\n          -  Use of any other hormonal contraceptive within 30 days of admission to the study site\n\n          -  Participants with abnormal papanicolaou (Pap) smear or CytoRich test"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127593", 
            "org_study_id": "CR104172", 
            "secondary_id": [
                "10131CON1001", 
                "2014-000983-16"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "First NGM/EE (Wet Process), then NGM/EE (Dry Process)", 
                    "First NGM/EE (Dry Process), then NGM/EE (Wet Process)"
                ], 
                "description": "Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.", 
                "intervention_name": "Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cyclen", 
                    "Tri Cyclen", 
                    "Cilest", 
                    "Tri-Cilest"
                ]
            }, 
            {
                "arm_group_label": [
                    "First NGM/EE (Wet Process), then NGM/EE (Dry Process)", 
                    "First NGM/EE (Dry Process), then NGM/EE (Wet Process)"
                ], 
                "description": "Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.", 
                "intervention_name": "Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Ortho Cyclen", 
                    "Ortho Tri Cyclen"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Ethinyl Estradiol", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate", 
                "Norgestimate", 
                "Norgestrel", 
                "Norgestimate, ethinyl estradiol drug combination", 
                "Moxifloxacin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Norgestimate", 
            "Ethinyl estradiol", 
            "Norgestrel", 
            "Norelgestromin", 
            "Ortho cyclen", 
            "Phase 1", 
            "Healthy Women"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of NGM/EE Tablets Manufactured at 2 Different Facilities", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "This study is not yet recruiting patients. Please check back for future recruiting sites, or email"
        }, 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "The Netherlands: Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The C(max) is the maximum serum concentration which will be observed at the defined time points.", 
                "measure": "Maximum Plasma Concentration (C[max])", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 72 hours after study drug administration on Day 1 of Period 1 and Period 2"
            }, 
            {
                "description": "The AUC (last) is the area under the plasma concentration-time curve from time zero time of the last quantifiable concentration C(last), and C(last) is the last observed quantifiable concentration.", 
                "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-last])", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 72 hours after study drug administration on Day 1 of Period 1 and Period 2"
            }, 
            {
                "description": "The AUC (infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time; and C(last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant.", 
                "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 72 hours after study drug administration on Day 1 of Period 1 and Period 2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127593"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The T[max] is time to reach the observed maximum plasma concentration.", 
                "measure": "Time to Reach the Maximum Plasma Concentration (T[max])", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 72 hours after study drug administration on Day 1 of Period 1 and Period 2"
            }, 
            {
                "description": "Percentage of AUC(0-infinity) is calculated as (AUC[0-infinity] minus AUC[0-last] divided by AUC[0-infinity]) multiplied by 100.", 
                "measure": "Percentage of AUC(0-infinity)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 72 hours after study drug administration on Day 1 of Period 1 and Period 2"
            }, 
            {
                "description": "Elimination half-life associated with the terminal slope (lambda[z]) of the semi logarithmic drug concentration-time curve, calculated as 0.693/lambda (z).", 
                "measure": "Elimination Half-life Period (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 72 hours after study drug administration on Day 1 of Period 1 and Period 2"
            }, 
            {
                "description": "Terminal slope is defined by first-order rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.", 
                "measure": "Terminal slope (Lambda [z])", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 72 hours after study drug administration on Day 1 of Period 1 and Period 2"
            }, 
            {
                "description": "The coefficient of determination is a goodness of fit statistic that gives the proportion of the variance of one variable that is predictable from the other variable.", 
                "measure": "Coefficient of Determination (r^2)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 72 hours after study drug administration on Day 1 of Period 1 and Period 2"
            }, 
            {
                "description": "The coefficient of determination adjusted (r^2 adj.) for the number of points used in the estimation of lambda[z].", 
                "measure": "Adjusted Coefficient of Determination (r^2 adj.)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 72 hours after study drug administration on Day 1 of Period 1 and Period 2"
            }
        ], 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}